Precancerous Conditions  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Precancerous Conditions
NCT00466115: A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies

Not yet recruiting
2
18
US
MS-275, GM-CSF
Johns Hopkins University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
 
04/07
NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer

Active, not recruiting
2
US
graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
 
 
NCT02188706: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
120
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Arsenic Trioxide, ATO, Trisenox
M.D. Anderson Cancer Center, TEVA, Leukemia SPORE
Leukemia
07/26
07/26

Download Options